Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men
The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Both estrogens and androgens play important roles in skeletal development and maintenance in men. The relative importance of estrogens and androgens in male bone metabolism, however, remains undefined. Anastrozole is an oral aromatase inhibitor that decreases estrogen production and increases androgen production in men. Currently, anastrozole is being investigated as a potential agent for the treatment of hypogonadism in aging men. Because anastrozole lowers estrogen levels and raises androgen levels, its effect on bone metabolism is difficult to predict. To assess the effects of anastrozole on bone turnover, we randomized 37 elderly (ages 62-74) mildly hypogonadal men (serum testosterone <350 ng/dl) to receive either anastrozole 1 mg daily (n=12), anastrozole 1 mg twice weekly (n=11), or daily placebo (n=14) for 12 weeks. Serum gonadal steroid levels, serum and urine biochemical markers of bone turnover, serum osteoprotegerin, and total body bone mineral density were measured at baseline and week 12. Mean serum levels of total and bioavailable testosterone increased substantially in both treated groups. Specifically, mean +/- SD bioavailable testosterone levels increased from 99+/-31 ng/dl to 207+/-65 ng/dl in the group receiving 1 mg of anastrozole daily and from 115+/-37 ng/dl to 178+/-55 ng/dl in the subjects receiving 1 mg of anastrozole twice weekly ( p <0.001 vs placebo for both groups). Serum estradiol levels decreased modestly in both treated groups (from 26+/-8 pg/m…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment with anastrozole daily for 6 months, however, did not result in a significant improvement compared with placebo [67].”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [67]
In the citing paper
“Results from the Leder trial reported no change in markers of bone turnover, despite greater mean reductions in estradiol”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [125]
In the citing paper
“while Burnett-Bowie’s group identified significant reductions in bone mineral density with therapy.”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [125]
In the citing paper
“Although one publication of men undergoing anastrozole therapy over a 3-month period demonstrated no significant change in markers of bone resorption, a subsequent 12-month study demonstrated direct radiologic evidence of bone mineral density loss despite unchanged markers of bone resorption.125, 126”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [125]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · cited 1×
“Furthermore, because estrogen replacement increases cardiovascular risk [28,29] and impairs cognitive function [30–32] in women, it is possible that aromatase inhibition may have unique benefits compared with traditional testosterone replacement in men in these areas as well.”
BackgroundLongitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471
Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., Hsia, J., Hulley, S., Herd, A., Khan, S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,930 · cited 1×
“Furthermore, because estrogen replacement increases cardiovascular risk [28,29] and impairs cognitive function [30–32] in women, it is possible that aromatase inhibition may have unique benefits compared with traditional testosterone replacement in men in these areas as well.”
BackgroundFeldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861 · cited 1×
“As men age there is a slow, steady decline in gonadal androgen production leading to a high incidence of hypogonadism [1–4].”
BackgroundMorishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530621 · Cited by 1,416 · cited 1×
“receptor-a gene or the aromatase gene are osteoporotic [51–53], and numerous epidemiological studies have reported associations between serum estradiol levels and BMD or fracture in adult men [54–62].”
BackgroundGRAY, A., FELDMAN, H. A., MCKINLAY, J. B., & LONGCOPE, C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1016 · Cited by 1,118 · cited 1×
“As men age there is a slow, steady decline in gonadal androgen production leading to a high incidence of hypogonadism [1–4].”
BackgroundRapp, S. R., Espeland, M. A., Shumaker, S. A., Henderson, V. W., Brunner, R. L., Manson, J. E., Gass, M. L. S., Stefanick, M. L., Lane, D. S., Hays, J., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2663 · Cited by 930 · cited 1×
“Furthermore, because estrogen replacement increases cardiovascular risk [28,29] and impairs cognitive function [30–32] in women, it is possible that aromatase inhibition may have unique benefits compared with traditional testosterone replacement in men in these areas as well.”
BackgroundTestosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.6.1661 · Cited by 922
Cited by
Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,200
“males (11), especially because similar small differences do not seem to cause BMD differences in pre- or perimenopausal women (12).”
BackgroundEstrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Sex Steroid Actions in Male Bone
Vanderschueren, D., Laurent, M. R., Claessens, F., Gielen, E., Lagerquist, M. K., Vandenput, L., Börjesson, A. E., & Ohlsson, C. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1024 · Cited by 327
A concise review of testosterone and bone health
Mohamad, N. V., Soelaiman, I.-N., & Chin, K.-Y. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s115472 · Cited by 292
Khera, M., Adaikan, G., Buvat, J., Carrier, S., El-Meliegy, A., Hatzimouratidis, K., McCullough, A., Morgentaler, A., Torres, L. O., & Salonia, A. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.10.009 · Cited by 177
Metadata
- Authors
- Leder, B. Z., & Finkelstein, J. S.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Leder, Benjamin Z.
- Venue
- Osteoporosis International
- Published
- 2005-04-23
- Volume
- 16
- Issue
- 12
- Pages
- 1487-1494
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2017930983
- Semantic Scholar
- 0d9c8160bde1b2e73e7bd92c06f1a5a75080cbd7
- Cited by
- 44
- References
- 78
- Citations by year
- 2024: 1 · 2022: 4 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 11 · 2015: 1 · 2014: 3 · 2012: 2
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K24DK002759)
- National Center for Research Resources (M01RR001066, K23RR016310, RR-1066)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- anastrozole, aromatase inhibitors, male hypogonadism, older men, bone metabolism, testosterone, estradiol, bone turnover markers, bone mineral density, osteoprotegerin, N-telopeptide, deoxypyridinoline, osteocalcin, androgen production, bone resorption, bone formation, hormone replacement therapy
- MeSH terms
- Anastrozole, Aged, Bone and Bones, Bone Resorption, Estradiol, Glycoproteins, Humans, Hypogonadism, Male, Nitriles, Testosterone, Triazoles, Biomarkers, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Aromatase Inhibitors, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. https://app.cochat.ai/papers/10.1007/s00198-005-1890-8
- The paper
- Leder, B. Z., & Finkelstein, J. S. (2005). Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporosis International. https://doi.org/10.1007/s00198-005-1890-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.